Condition: Coronary Artery Disease · Sponsor: Yonsei University
Comparison of * Biolimus-eluting stent, Biomatrix, or Biomatrix Flex stent, Biosensors, Singapore * Everolimus-eluting stent, Xience V, or Xience Prime, or Xience Xpedition stent, Abbott, USA * Zotarolimus-eluting stent, Endeavor Resolute, or Endeavor Resolute Integrity stent Medtronic, USA in patients with coronary artery disease treated with percutaneous coronary intervention
This description comes directly from the study's public registry record.
Junghan Yoon, M.D., Ph.D. · +82-33-741-0906 · jyoon@yonsei.ac.kr
Young Jin Youn, M.D. · +82-33-741-0917 · younyj@yonsei.ac.kr
Always discuss trial participation with your own doctor first.
| Chuncheon Hallym University Hospital | Chuncheon, Gangwon-do, South Korea | Not Yet Recruiting |
| Yonsei University Wonju Christian Hospital | Wŏnju, Gangwon-do, South Korea | Recruiting |
| Korea University Guro Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02038127